Ninewells Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study

  NCT07522528· University of Glasgow· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

  NCT06843239· Phase 2· Zura Bio Inc· Source

• Recruiting

  Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

  NCT06435156· Phase 2· University of Dundee· Source

• Recruiting

  A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  NCT06672549· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

  NCT06672939· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Recruiting

  A Study of Pitolisant in Patients With Prader-Willi Syndrome

  NCT06366464· Phase 3· Harmony Biosciences Management, Inc.· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

  NCT05846230· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  HTL0039732 in Participants With Advanced Solid Tumours

  NCT05944237· Phase 1/2· Cancer Research UK· Source

• Active, not recruiting

  CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Recruiting

  A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

  NCT06461208· Phase 3· King's College London· Source

• Active, not recruiting

  A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

  NCT05926765· Phase 2· MeiraGTx, LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The Role of Circulating Tumour DNA in Head and Neck Cancer

  NCT05539638· University of Edinburgh· Source

• Recruiting

  Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

  NCT05604963· University College, London· Source

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

  NCT04704934· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

  NCT04871919· Alfasigma S.p.A.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· University of Leicester· Source

• Recruiting

  Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

  NCT04302870· Phase 2/3· University of Edinburgh· Source

• Active, not recruiting

  Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

  NCT04083339· Phase 3· Applied Therapeutics, Inc.· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

  NCT02406222· Phase 2· University of Leeds· Source

• Recruiting

  NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

  NCT02817360· Phase 4· Martin Huelsmann· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity4 recruiting
• Bronchiectasis3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Heart failure3 recruiting
• Type 2 diabetes3 recruiting
• Crohn's disease2 recruiting
• Multiple myeloma2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Cystic fibrosis1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Lung cancer1 recruiting
• Mesothelioma1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Completed

  A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

  NCT05659264· Phase 1· ModernaTX, Inc.· Source

• Completed

  Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

  NCT05419115· Phase 2· NHS Greater Glasgow and Clyde· Source

• Completed

  Virtual Peer-to-peer Support Programme for Carers of MND

  NCT04695210· King's College London· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  Predicting Endoleaks Following Endovascular Aortic Aneurysm Repair Using 18F-Sodium Fluoride

  NCT04577716· University of Edinburgh· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Concept Medical Inc.· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bronchiectasis46 works · 5 trials